Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives

Abstract excerpt

Among Uveal Melanoma (UM) driver mutations, those involving GNAQ or GNA11 genes are the most frequent, while a minor fraction of tumors bears mutations in the PLCB4 or CYSLTR2 genes. Direct inhibition of constitutively active oncoproteins deriving from these mutations is still in its infancy in UM, whereas BRAFV600E-targeted therapy has obtained relevant results in cutaneous melanoma. However, UM driver mutations...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Ocular Oncology and Treatments
• Share to Protein Degradation and Inhibitors
• Share to Ubiquitin and proteasome pathways